Eurofins' AI Aims to Revolutionize Early-Stage Drug Formulation

MISSISSAUGA, Ontario – January 26, 2026 – In a move that signals a significant leap forward for pharmaceutical development, Eurofins CDMO Alphora has announced the launch of a proprietary AI-powered software designed to streamline one of the most critical and complex stages of creating new medicines. The new platform, developed in collaboration with a local university, uses machine learning to predict the optimal solid form of a drug, a breakthrough that promises to shorten development timelines, reduce costs, and accelerate the delivery of new therapies to patients.

The software focuses on high-throughput salt and co-crystal screening for Active Pharmaceutical Ingredients (APIs) and their intermediates. It is now a core component of all solid-state screening programs at the Mississauga-based contract development and manufacturing organization (CDMO).

The Decades-Old Challenge of Solid-Form Selection

Before a new drug can be put into a tablet or capsule, scientists must determine its most effective and stable physical form. The vast majority of drugs are administered as solids, but the same API can exist in multiple crystalline structures, known as polymorphs, salts, or co-crystals. This choice is far from trivial; the selected solid form directly dictates a drug's most important properties, including its solubility, shelf-life stability, and bioavailability—the rate at which it is absorbed by the body.

Traditionally, finding the ideal form has been a resource-intensive and often unpredictable process. It involves a laborious series of trial-and-error experiments, where scientists test hundreds or even thousands of conditions in the lab. This empirical approach consumes significant amounts of valuable API, takes months to complete, and carries no guarantee of success. An inefficient solid form can lead to poor patient outcomes or manufacturing hurdles, sometimes forcing a promising drug candidate back to the drawing board.

This fundamental challenge has long been a bottleneck in the pharmaceutical pipeline, adding time and cost to a process where both are in critically short supply. The industry has been searching for a way to make this process smarter, faster, and more predictable.

AI as the Solution: Predictive Power in Pharma

Eurofins CDMO Alphora's new platform represents a paradigm shift away from this experimental grind. By leveraging sophisticated machine learning models, the software can analyze the molecular structure of an API and accurately predict its likelihood of forming stable and effective salts or co-crystals with various other compounds. Instead of casting a wide, physical net, researchers can now use the AI to intelligently narrow down the field to a handful of high-probability candidates for experimental verification.

This predictive capability drastically minimizes the need for exhaustive benchtop screening. The company states the tool empowers clients to make smarter, data-driven decisions much earlier in the development lifecycle. For pharmaceutical companies, this means a faster path to an optimized solid form, reducing the risk of late-stage failures and conserving precious development resources.

The user-friendly interface is designed to integrate seamlessly into the workflow of Eurofins CDMO Alphora’s Solid-State R&D team, which guides clients through interpreting the AI's predictions and designing targeted experimental strategies. This combination of cutting-edge technology and human expertise ensures that the insights generated by the algorithm are translated into practical, effective development plans.

A New Competitive Edge in the CDMO Market

The announcement places Eurofins CDMO Alphora at the forefront of a major industry trend: the evolution of CDMOs from simple service providers to indispensable innovation partners. As pharmaceutical companies increasingly outsource R&D and manufacturing, they are looking for partners who can provide not just capacity, but also a technological edge.

This AI-driven offering is a clear differentiator in a competitive market. While other major industry players like Merck Group have also introduced AI-based prediction services for co-crystals, the integration of such a tool as a core component of a CDMO's standard offering is a significant move. It reflects a broader digital transformation within the pharmaceutical manufacturing sector, where companies like Lonza, Catalent, and Thermo Fisher Scientific are increasingly investing in AI, predictive analytics, and digital twins to optimize processes and accelerate timelines.

By embedding advanced AI into its services, Eurofins CDMO Alphora can offer integrated solutions that improve not only a drug's bioavailability but also its manufacturability. This cross-departmental approach, linking solid-state chemistry with drug substance and product development teams "under one roof," provides clients a holistic path from molecule to medicine.

Navigating the Future of AI in Regulated Drug Development

While the potential of AI in drug development is immense, its implementation comes with significant responsibilities, particularly regarding regulatory oversight. Global bodies like the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) are actively developing frameworks for the use of AI and machine learning tools in pharmaceutical submissions.

The key to regulatory acceptance is transparency and validation. Regulators are wary of "black box" algorithms and require that companies can explain and defend the decisions made by their AI systems. This means the models must be trained on high-quality, curated datasets, and their predictive outputs must be rigorously validated against experimental results.

The successful deployment of tools like Eurofins CDMO Alphora’s platform will depend on maintaining this high standard of data integrity and scientific rigor. As AI becomes more prevalent, its role will be not to replace the scientist, but to augment their capabilities, ensuring that innovation is pursued safely and effectively. This new technology is a powerful example of how digital transformation can address long-standing scientific challenges, ultimately streamlining the complex journey of bringing new and improved medicines to the market.